Transcript Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia
*BPH is the most common benign tumor in men.
*Its age related disease.
( when the hair become grey &scanty,
when specks of earthy matter begin to deposit in
tunica of artery,
when white zone is formed at the margin of cornea,
at this same period the prostate gland usually, if not
invariably, enlarge.)
Anatomically
the prostate had 3 zones
-peripheral (70%) of the prostate commonest site for
Ca,
-central (25%) around ejaculatory duct, &
-transitional (5%) periurethral.
BPH uniformly originate from the transitional zone
& as the nodule enlarge compress the outer zones of
the prostate resulting in surgical capsule.
Benign Prostatic Hyperplasia

4/6/2017
Generalised disease of the
prostate due to hormonal
derangement which leads
to enlargement of the
gland (increase in the
number of epithelial cells
and stromal tissue)to cause
compression of the urethra
leading to symptoms
4
BPH
Proposed Etiologies






Cause not completely understood
Reawakening of the urogenital sinus to proliferate
Change in hormonal milieu with alterations in the
testosterone/estrogen balance
Induction of prostatic growth factors
Increased stem cells/decreased stromal cell death
Accumulation of dihydroxytestosterone, stimulation by
estrogen and prostatic growth hormone actions
BPH facts




Occurs in 50% of men over 50 and in 80% of
men over 80 have BPH
BPH progresses differently in every individual
Many men with BPH may have mild
symptoms and may never need treatment
BPH does not predispose to the
development of prostate cancer
4/6/2017
6
Benign Prostatic Hyperplasia
4/6/2017
7
BPH Pathophysiology
Normal
BPH
BLADDER
PROSTATE
URETHRA
Hypertrophied
detrusor muscle
Obstructed
urinary flow
Kirby RS et al. Benign prostatic hyperplasia. Health Press, 1995.
BPH
Pathophysiology



Slow and insidious changes over time
Complex interactions between prostatic urethral
resistance, intravesical pressure, detrussor
functionality, neurologic integrity, and general
physical health.
Initial hypertrophydetrussor decompensation
poor tonediverticula formationincreasing urine
volumehydronephrosisupper tract dysfunction
Complications








Urinary retention
UTI
Sepsis secondary to UTI
Residual urine
Calculi
Renal failure
Hematuria
Hernias, hemorroids, bowel habit change
4/6/2017
10
Clinical manifestations

Voiding symptoms

decrease in the urinary stream

Straining

Dribbling at the end of urination

Intermittency

Hesitancy

Pain or burning during urination

Feeling of incomplete bladder emptying
4/6/2017
11
Clinical manifestations

Irritative symptoms
urinary frequency
urgency
dysuria
bladder pain
nocturia
incontinence
symptoms associated with infection
4/6/2017
12
Benign Prostatic Hyperplasia
•
Leading to “symptom bother” and
worsened QOL
Other Relevant History




GU History (STD, trauma, surgery)
Other disorders (eg. neurologic,
diabetes)
Medications (anti-cholinergics)
Functional Status
Diagnostic Tests

History & Examination







Abdominal/GU exam
Focused neuro exam
Digital rectal exam (DRE)
Validated symptom
questionnaire.
Urinalysis
Urine culture
BUN, Cr
4/6/2017




Prostate specific
antigen (PSA)
Transrectal
ultrasound – biopsy
Uroflometry
Postvoid residual
15
AUA Symptom Score Sheet
Not at all
Less
than 1
time
in 5
Less
than
half the
time
About
half the
time
More
than
half
the
time
Almost
always
0
1
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
None
1 time
2 times
3 times
4 times
5 times
or more
0
1
2
3
4
5
Your
score
Incomplete emptying
Over the past month, how often have you had a sensation of not emptying your
bladder completely after you finish urinating?
Frequency
Over the past month, how often have you had to urinate again less than two hours
after you finished urinating?
Intermittency
Over the past month, how often have you found you stopped and started again several
times when you urinated?
Urgency
Over the last month, how difficult have you found it to postpone urination?
Weak stream
Over the past month, how often have you had a weak urinary stream?
Straining
Over the past month, how often have you had to push or strain to begin urination?
Your
score
Nocturia
Over the past month, many times did you most typically get up to urinate from the
time you went to bed until the time you got up in the morning?
Quality of life due to urinary symptoms
If you were to spend the rest of your life with your
urinary condition the way it is now, how would you
feel about that?
Delighted
Pleased
Mostly satisfied
Mixed – about equally
satisfied and dissatisfied
Mostly
dissatisfied
Unhappy
Terrible
0
1
2
3
4
5
6
Total score: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.
DRE
4/6/2017
17
BPH
Danger Signs on DRE





Firm to hard nodules
Irregularities, unequal lobes
Induration
Stony hard prostate
Any palpable nodular abnormality
suggests cancer and warrants
investigation
Optional Evaluations and
Diagnostic Tests




Urine cytology in patients with:
 Predominance of irritative voiding symptoms.
 Smoking history
Flow rate and post-void residual
 Not necessary before medical therapy but should be
considered in those undergoing invasive therapy or
those with neurologic conditions
Upper tract evaluation if hematuria, increased creatinine
Cystoscopy
PSA

Elevated levels of PSA

0 – 4 ng/ml



Prostatic pathology
Correlates with tumor mass
Some men with prostate cancer have
normal PSA levels
4/6/2017
21
BPH SYMPTOMS
Differential Diagnosis







Urethral stricture
Bladder neck contracture
Carcinoma of the prostate
Carcinoma of the bladder
Bladder calculi
Urinary tract infection and prostatitis
Neurogenic bladder
BPH TREATMENT
INDICATIONS
Absolute vs Relative



Severe obstruction
Urinary retention
Signs of upper tract
dilatation and renal
insufficiency




Moderate symptoms
of prostatism
Recurrent UTI’s
Hematuria
Quality of life issues
Treatment Options

Mild to severe symptoms with little
“bother”

Manage with watchful waiting.


Risk of therapy outweighs the benefit of
medical or surgical treatment
Moderate to severe symptoms with
bother

Management options include watchful
waiting, medical management and surgical
treatment.
Therapy


Watchful waiting and behavioral modification
Medical Management




Surgical Management



Alpha blockers
5-alpha reductase inhibitors
Combination therapy
Office based therapy
OR based therapy
Urethral stents
Watchful Waiting and Behavioral
Modification

“is the preferred management technique in
patients with mild symptoms and minimal
bother”

AUA score < 7,

1/3 improve on own.
Watchful Waiting and Behavioral
Modification





Decrease caffeine, alcohol )diuretic effect(
Avoid taking large amounts of fluid over a short
period of time
Void whenever the urge is present, every 2-3 hours
Maintain normal fluid intake, do not restrict fluid
Avoid bladder irritants to include dairy products,
artificial sweeteners, carbonated beverages

Limit nighttime fluid consumption

BPH symptoms can be variable, intermittent
Medical Management
•
•
•
•
Nutritional supplements
–
Saw Palmetto
–
Doxazosin (Cardura), Terazosin (Hytrin),
Tamsulosin (Flomax), Alfuzosin (Uroxatral)
Alpha blockers
5-alpha reductase inhibitors
–
Finasteride (Proscar), Dutasteride (Avodart)
–
Alpha blocker and 5-alpha reductase inhibitor
Combination therapy
medication
Benefits



Disadvantages
Convenient

Expensive
No loss of work
time

Drug Interactions

Must be taken every day
Minimal risk

Manages the problem
instead of fixing it
Medical Management
Alpha adrenergic receptor blockers
 promote smooth muscle relaxation in the prostate
 Relaxation of the muscles facilitates urinary flow
 Doxazosin (Cardura), Terazosin (Hytrin), Tamsulosin
(Flomax), Alfuzosin (Uroxatral)
 Side effects: postural hypotension, dizziness, fatigue,
 Other problems can occur when pt is also taking
cardiac or other hypertensive drugs
4/6/2017
30
Alpha-Adrenergic Blockers


Equal clinical effectiveness
Slight differences in adverse event profile






Orthostasis (lower in tamsulosin)
Ejaculatory dysfunction (higher in tamsulosin)
Decreased energy levels
Nasal congestion
Increase in CHF risk with doxazosin
Must titrate doxazosin and terazosin to
effective levels
Medical Management
5 alpha reductase inhibitor )finasteride :Proscar(
 Reduce size of prostate gland by up to 30 %
 Blocks the enzyme of 5 alpha reductase which is
nec, for the conversion of testosterone to
dihydroxytestostersone
 Regression of hyperplastic growth
 Don’t work immediately
 Small effect on symptom score and flow rates
4/6/2017
32
5-Alpha Reductase Inhibitors

Agents are effective and appropriate treatment for
patients with lower urinary tract symptoms and
demonstrable enlargement of the prostate.

Average prostate size is 30 cc’s. Original studies
showed benefit only in men with prostate sizes
greater than 50 cc’s.
5-Alpha Reductase Inhibitors

Finasteride (Proscar) and Dutasteride (Avodart)
 Less effective for relief of BPH symptoms
than alpha blockers
 Adverse events include
 Decreased libido
 Worsened sexual function (erectile dysfunction)
 decrease volume of ejaculation
 Breast enlargement and tenderness
 Reduces risk of urinary retention by 3%/year.
 PSA must be doubled if screening for prostate
cancer
Combination Therapy

Concomitant use of alpha blockers and
5-alpha reductase inhibitors

Should be reserved for patients who
are at significant risk of progression
and adverse outcome



Poor surgical candidate
Patient wants to avoid surgery
Significant cost associated with dual
medications
Medical Management


Herbal therapy –
saw palmetto fruit –
use to improve
urinary symptoms
and urinary flow
Problem with herbal
therapy – long term
effectiveness
4/6/2017
36
surgical treatment
Surgical Management

Office based therapies:


Transurethral microwave therapy (TUMT)
Transurethral needle ablation (TUNA)
 Therapies are effective
or partially effective for
relieving the symptoms of BPH
 Significant side effects/complications
associated with these treatments
have prompted a FDA warning
Surgical Management

OR based therapies





Open simple prostatectomy
TURP
Transurethral incision of the prostate
Laser photoselective vaporization of the
prostate (green light laser PVP)
Laser Prostatectomy
Surgical Management



Patients may select surgical treatment as initial
therapy if moderate or severe bother is present.
Patients who have developed complications of
BPH (i.e urinary retention, renal insufficiency,
recurrent UTI) are best treated surgically.
New surgical treatment have not demonstrated
better outcomes than TURP to date.
BPH TREATMENT
Surgical




Indicated for AUA score >16
Transurethral Prostatectomy(TURP): 18%
morbidity with .2% mortality. 80-90%
improvement at 1 year but 60-75% at 5 years
and 5% require repeat TURP.
Transurethral Incision of Prostate (TUIP): less
morbidity with similar efficacy indicated for
smaller prostates.
Open Prostatectomy: indicated for glands >
60 grams or when additional procedure
needed for suprapubic/retropubic approaches
TURP

“Gold Standard” of care for BPH
the “gold standard”- TURP
Disadvantages
Benefits

Widely available

Effective

Long lasting

Greater risk of side
effects and complications

1-4 days hospital stay

1-3 days catheter

4-6 week recovery
possible side effects of

TURP
Greater than 5% risk of:



Irritative voiding symptoms
Bladder neck contracture
UTI
Risk of incontinence 1%
Decline in erectile function
65% of retrograde ejaculation
TUR syndrome (acute hyponatremia from free
water absorption)
Hemorrhage
Bladder spasms

Preoperative Goals



Restoration of urinary drainage
Treatment of any urinary tract infection
Understanding of procedure,
implications for sexual functioning and
urinary control
4/6/2017
45
Preoperative care



Antibiotics
Allow pt to discuss concerns about
surgery on sexual functioning
Prostatic surgery may result in
retrograde ejaculation
4/6/2017
46
Postoperative Goals




No complications
Restoration of urinary control
Complete bladder emptying
Satisfying sexual expression
4/6/2017
47
Postoperative Care




Monitoring
Continuous irrigation & maintain catheter
patency
Blood clots and hematuria are expected for
the first 24-36 hours
After catheter is removed – check for urinary
retention and urinary stream
4/6/2017
48
TURP



Sphincter tone may be poor after
catheter is removed. Kegal exercise
pelvic muscle floor technique is
encouraged. Starting and stopping the
urinary stream is helpful.
Stool softeners to avoid straining
Sitting and walking for long periods
should be avoided
4/6/2017
49
Discharge planning







Catheter care
Managing urinary incontinence
Oral fluid intake – 2,000-3,000 cc per day
Observe for s/s of urinary tract infection
Prevent constipation
Avoid lifting
No driving or intercourse after surgery
4/6/2017
50
Surgical approaches for
prostatectomy

Retropubic


Perineal


Midline abd. incision
Incision between the
scrotum and anus
Suprapubic

4/6/2017
Abdominal incision
51
Prostatectomy

Complications:




Bleeding
Postoperative pain
Risk for infection
Erectile dysfunction
4/6/2017
52
BPH TREATMENT
New Modalities



Minimally invasive: (Prostatic
Stents,TUNA,TUMT, HIFU,Waterinduced Thermotherapy)
Laser prostatectomy
(VLAP,ILC,CLAP,TULIP,HoLRP)
Electrovaporization (TUVP,TVRP)
heat therapies
 Destroy
prostate tissue with heat
 Tissue
is left in the body and is expelled
over time (called sloughing)

Transurethral Microwave Therapy (TUMT)

Transurethral Needle Ablation (TUNA®)

Interstitial Laser Coagulation (ILC)

Water Induced Thermotherapy (WIT)
heat therapies



Benefits
Office treatments
Local anesthesia
Minimally invasive

Reduced risk of
complications as
compared to
invasive surgical
“TURP”
Disadvantages



Some symptoms will
persist for up to 3
months
Cannot predict who will
respond
May require prolonged
catheterization
possible side effects of
heat therapies

Urinary Tract Infection

Impotence

Incontinence
Laser Photoselective Vaporization
of the Prostate (Laser PVP)



TURP-equivalent 7 year improvement in
symptom score and urination parameters
Decreased risk of bleeding and TUR
syndrome, otherwise similar adverse effect
profile
May be done on anti-coagulated patients